[go: up one dir, main page]

WO2001068140A3 - Formulations opioides - Google Patents

Formulations opioides Download PDF

Info

Publication number
WO2001068140A3
WO2001068140A3 PCT/US2001/006955 US0106955W WO0168140A3 WO 2001068140 A3 WO2001068140 A3 WO 2001068140A3 US 0106955 W US0106955 W US 0106955W WO 0168140 A3 WO0168140 A3 WO 0168140A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
fentanyl
concentration
subject
further provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/006955
Other languages
English (en)
Other versions
WO2001068140A2 (fr
Inventor
Dana Litmanovitz
Barbara J F Laidlaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Durect Corp
Original Assignee
Durect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2001243414A priority Critical patent/AU2001243414B2/en
Priority to CA002402865A priority patent/CA2402865A1/fr
Priority to JP2001566703A priority patent/JP4969009B2/ja
Priority to US10/220,525 priority patent/US7074803B2/en
Priority to AU4341401A priority patent/AU4341401A/xx
Application filed by Durect Corp filed Critical Durect Corp
Publication of WO2001068140A2 publication Critical patent/WO2001068140A2/fr
Publication of WO2001068140A3 publication Critical patent/WO2001068140A3/fr
Priority to US10/188,325 priority patent/US6835194B2/en
Anticipated expiration legal-status Critical
Priority to US10/922,239 priority patent/US20050106205A1/en
Priority to US13/355,217 priority patent/US20120239007A1/en
Priority to US14/260,181 priority patent/US20140350053A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des formulations à teneur élevée en opioïdes, notamment le fentanyl ou les congénères de fentanyl. La formulation de cette invention contient du fentanyl ou un congénère de fentanyl dans des proportions particulièrement élevées par rapport aux formulations classiques, par exemple, dans l'ordre d'environ 2 fois à environ 10 000 supérieures aux formulations classiques, notamment, les formulations actuellement disponibles dans le commerce. Ces formulations sont particulièrement utiles dans le cadre d'une administration à long terme à un sujet souffrant de douleur. En outre, cette invention concerne des dispositifs d'administration de médicaments renfermant ces formulations à teneur élevée en opioïdes, et concerne également des méthodes permettant d'atténuer la douleur chez un sujet, consistant à lui administrer ces formulations à teneur élevée en opioïdes.
PCT/US2001/006955 1999-03-18 2001-03-02 Formulations opioides Ceased WO2001068140A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2001243414A AU2001243414B2 (en) 2000-03-10 2001-03-02 Opioid formulations
CA002402865A CA2402865A1 (fr) 2000-03-10 2001-03-02 Formulations opioides
JP2001566703A JP4969009B2 (ja) 2000-03-10 2001-03-02 オピオイド製剤
US10/220,525 US7074803B2 (en) 2001-03-02 2001-03-02 Opioid formulations
AU4341401A AU4341401A (en) 2000-03-10 2001-03-02 Opioid formulations
US10/188,325 US6835194B2 (en) 1999-03-18 2002-06-27 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US10/922,239 US20050106205A1 (en) 1999-03-18 2004-08-18 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US13/355,217 US20120239007A1 (en) 1999-03-18 2012-01-20 Implantable Devices and Methods for Treatment of Pain by Delivery of Fentanyl and Fentanyl Congeners
US14/260,181 US20140350053A1 (en) 2000-03-10 2014-04-23 Opioid formulations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18826300P 2000-03-10 2000-03-10
US60/188,263 2000-03-10

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/522,535 Continuation-In-Part US6541021B1 (en) 1999-03-18 2000-03-10 Devices and methods for pain management

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US10/220,525 A-371-Of-International US7074803B2 (en) 2000-03-10 2001-03-02 Opioid formulations
PCT/US2001/043143 Continuation-In-Part WO2002043800A2 (fr) 1999-03-18 2001-11-21 Dispositifs et procedes de liberation controlee pour instrument d'administration de medicaments
US10/188,325 Continuation-In-Part US6835194B2 (en) 1999-03-18 2002-06-27 Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
US11/477,140 Continuation US20070014820A1 (en) 2000-03-10 2006-06-27 Opioid formulations

Publications (2)

Publication Number Publication Date
WO2001068140A2 WO2001068140A2 (fr) 2001-09-20
WO2001068140A3 true WO2001068140A3 (fr) 2001-12-13

Family

ID=22692427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/006955 Ceased WO2001068140A2 (fr) 1999-03-18 2001-03-02 Formulations opioides

Country Status (4)

Country Link
JP (1) JP4969009B2 (fr)
AU (2) AU4341401A (fr)
CA (1) CA2402865A1 (fr)
WO (1) WO2001068140A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
KR100912307B1 (ko) * 2004-10-21 2009-08-14 유니버시티 오브 아이오와 리써치 파운데이션 동일계내 제어된 방출 약물 전달 시스템
US20140179740A1 (en) * 2012-12-21 2014-06-26 Mylan Inc. Stable liquid remifentanil formulations
JP6081240B2 (ja) * 2013-03-13 2017-02-15 テルモ株式会社 レミフェンタニル注射液剤
WO2016038734A1 (fr) 2014-09-12 2016-03-17 テルモ株式会社 Injection de rémifentanil
US20180117012A1 (en) * 2016-10-31 2018-05-03 Teikoku Pharma Usa, Inc. Methods of Managing Pain Using Dexmedetomidine Transdermal Delivery Devices

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588580A (en) * 1984-07-23 1986-05-13 Alza Corporation Transdermal administration of fentanyl and device therefor
WO1990007333A1 (fr) * 1989-01-06 1990-07-12 Riker Laboratories, Inc. Compositions aerosols contenant du fentanyle
WO1997049402A1 (fr) * 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. Compositions de sufentanil a liberation prolongee
US5910301A (en) * 1994-05-13 1999-06-08 Aradigm Corporation Method of intrapulmonary administration of a narcotic drug
WO2000054745A2 (fr) * 1999-03-18 2000-09-21 Durect Corporation Dispositifs et methodes utilises pour soulager la douleur

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
JPH05331064A (ja) * 1992-05-26 1993-12-14 Sekisui Chem Co Ltd 消炎鎮痛貼付剤
JPH07206903A (ja) * 1994-01-24 1995-08-08 Takeda Chem Ind Ltd 超分子構造型集合体
JPH09176000A (ja) * 1995-12-28 1997-07-08 Teijin Ltd 医療用貼付剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588580A (en) * 1984-07-23 1986-05-13 Alza Corporation Transdermal administration of fentanyl and device therefor
US4588580B1 (fr) * 1984-07-23 1989-01-03
US4588580B2 (en) * 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
WO1990007333A1 (fr) * 1989-01-06 1990-07-12 Riker Laboratories, Inc. Compositions aerosols contenant du fentanyle
US5910301A (en) * 1994-05-13 1999-06-08 Aradigm Corporation Method of intrapulmonary administration of a narcotic drug
WO1997049402A1 (fr) * 1996-06-27 1997-12-31 Janssen Pharmaceutica N.V. Compositions de sufentanil a liberation prolongee
WO2000054745A2 (fr) * 1999-03-18 2000-09-21 Durect Corporation Dispositifs et methodes utilises pour soulager la douleur

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1995, RAMSAY E C ET AL: "Immobilization of black bears (Ursus americanus) with orally administered carfentanil citrate.", XP002175618, Database accession no. PREV199598404995 *
JOURNAL OF WILDLIFE DISEASES, vol. 31, no. 3, 1995, pages 391 - 393, ISSN: 0090-3558 *

Also Published As

Publication number Publication date
JP2003526680A (ja) 2003-09-09
WO2001068140A2 (fr) 2001-09-20
JP4969009B2 (ja) 2012-07-04
AU2001243414B2 (en) 2005-05-19
AU4341401A (en) 2001-09-24
CA2402865A1 (fr) 2001-09-20

Similar Documents

Publication Publication Date Title
WO2002015903A3 (fr) Nouvelle composition pharmaceutique permettant l'administration de n-0923
PL1708686T3 (pl) Doustna forma dawkowania fentanylu w postaci musującej o charakterze liniowym oraz sposoby jego podawania
IL176452A0 (en) Effervescent oral opiate dosage form
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
WO2003030829A3 (fr) Preparations d'insuline encapsulees dans des liposomes
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2003301190A1 (en) Administration of capsaicinoids
WO2004043363A8 (fr) Preparations liposomales d'agents pharmaceutiques stabilisees par des proteines
SE0102276D0 (sv) Device and method for the administration of a medicament
WO2001090091A8 (fr) Inhibiteurs de 11-beta-hydroxy-steroide-deshydrogenase de type 1
PT1412384E (pt) Formulação estável de glp-1 modificado
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
WO1999053910A3 (fr) Compositions pharmaceutiques contenant de l'acide folique, procedes et systemes d'administration correspondants
WO2003045306A3 (fr) Composes phenoxy amine et compositions pour administrer des principes actifs
MXPA03007857A (es) Compuestos y composiciones para entregar agentes activos.
IL136591A (en) Nasal pharmaceutical solutions
IL179718A0 (en) Pharmaceutical composition containing irbesartan
WO2000050046A8 (fr) Composition pharmaceutique orale stabilisee contenant de l'iodure et de l'iodate et procede associe
WO2000078294A3 (fr) Forme galenique orale servant a administrer une combinaison fixe de tramadol et de diclofenac
WO2002070524A3 (fr) N-but-3-enyl norbuprenorphine et utilisations
WO2002030405A3 (fr) Traitement de troubles affectifs par l'action combinee d'un agoniste du recepteur nicotinique et d'une substance monoaminergique
MXPA06000332A (es) Nueva composicion farmaceutica solida que comprende amisulprida.
WO2001068140A3 (fr) Formulations opioides
WO2004056347A3 (fr) Compositions d'insuline stabilisees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001243414

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 566703

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2402865

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10220525

Country of ref document: US

122 Ep: pct application non-entry in european phase
WWG Wipo information: grant in national office

Ref document number: 2001243414

Country of ref document: AU